GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » FCF Margin %

Apollomics (Apollomics) FCF Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Apollomics's Free Cash Flow for the six months ended in Dec. 2023 was $-18.81 Mil. Apollomics's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Apollomics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Apollomics's current FCF Yield % is -139.66%.

The historical rank and industry rank for Apollomics's FCF Margin % or its related term are showing as below:


APLMW's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -141.025
* Ranked among companies with meaningful FCF Margin % only.

Apollomics FCF Margin % Historical Data

The historical data trend for Apollomics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics FCF Margin % Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
FCF Margin %
- - - -

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
FCF Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Apollomics's FCF Margin %

For the Biotechnology subindustry, Apollomics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollomics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Apollomics's FCF Margin % falls into.


Apollomics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Apollomics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-43.215/0
= %

Apollomics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-18.812/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Apollomics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollomics (Apollomics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » FCF Margin %
Comparable Companies
ATHA STTK ACXP CARA TLSA ORMP IMMX CCCC GTHX GBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
APLM:USA
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Website
https://www.apollomicsinc.com
Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.